Varzavand Afshin, Hacker Will, Ma Deqin, Gibson-Corley Katherine, Hawayek Maria, Tayh Omar J, Brown James A, Henry Michael D, Stipp Christopher S
Department of Biology, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa.
Department of Biochemistry, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, Iowa.
Cancer Res. 2016 Nov 15;76(22):6577-6587. doi: 10.1158/0008-5472.CAN-16-1483. Epub 2016 Sep 28.
Existing anticancer strategies focused on disrupting integrin functions in tumor cells or tumor-involved endothelial cells have met limited success. An alternative strategy is to augment integrin-mediated pathways that suppress tumor progression, but how integrins can signal to restrain malignant behavior remains unclear. To address this issue, we generated an in vivo model of prostate cancer metastasis via depletion of α3β1 integrin, a correlation observed in a significant proportion of prostate cancers. Our data describe a mechanism whereby α3β1 signals through Abl family kinases to restrain Rho GTPase activity, support Hippo pathway suppressor functions, and restrain prostate cancer migration, invasion, and anchorage-independent growth. This α3β1-Abl kinase-Hippo suppressor pathway identified α3 integrin-deficient prostate cancers as potential candidates for Hippo-targeted therapies currently under development, suggesting new strategies for targeting metastatic prostate cancer based on integrin expression. Our data also revealed paradoxical tumor suppressor functions for Abl kinases in prostate cancer that may help to explain the failure of Abl kinase inhibitor imatinib in prostate cancer clinical trials. Cancer Res; 76(22); 6577-87. ©2016 AACR.
现有的针对破坏肿瘤细胞或肿瘤相关内皮细胞中整合素功能的抗癌策略取得的成功有限。另一种策略是增强整合素介导的抑制肿瘤进展的信号通路,但整合素如何发出信号来抑制恶性行为仍不清楚。为了解决这个问题,我们通过消耗α3β1整合素建立了一种前列腺癌转移的体内模型,这种相关性在相当比例的前列腺癌中都有观察到。我们的数据描述了一种机制,即α3β1通过Abl家族激酶发出信号,抑制Rho GTPase活性,支持Hippo信号通路抑制功能,并抑制前列腺癌的迁移、侵袭和非锚定依赖性生长。这种α3β1-Abl激酶-Hippo抑制信号通路确定α3整合素缺陷型前列腺癌是目前正在开发的Hippo靶向治疗的潜在候选对象,这为基于整合素表达靶向转移性前列腺癌提出了新策略。我们的数据还揭示了Abl激酶在前列腺癌中具有矛盾的肿瘤抑制功能,这可能有助于解释Abl激酶抑制剂伊马替尼在前列腺癌临床试验中的失败。《癌症研究》;76(22);6577 - 87。©2016美国癌症研究协会。